Novacyt
S.A.
("Novacyt", the "Company" or
the "Group")
AGM voting
Paris, France,
and Eastleigh and Manchester, UK - 3 June 2024 -
Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an
international molecular diagnostics company with a broad portfolio
of integrated technologies and services, will be holding its annual general meeting ("AGM")
exclusively as an open online meeting
at 2pm CEST/1pm BST on Wednesday, 26 June 2024. As
usual, and in accordance with French corporate law, the AGM
comprises both ordinary and extraordinary resolutions. All
materials can be found at www.novacyt.com/investors.
Shareholders are strongly encouraged to submit
their votes in advance, in accordance with the instructions in the
Notice of the AGM.
Under French law, for the AGM and EGM meetings
to be quorate at the first attempt, shareholders representing at
least 20% of the share capital and voting rights, on ordinary
resolutions, and 25% of the share capital and voting rights, on
extraordinary resolutions, must be present, represented or have
voted in advance under the conditions set out below.
Shareholders can vote in advance of the AGM
by:
• Downloading a copy of the proxy
voting form from the website www.novacyt.com/investors,
completing it and returning it together with evidence of their
shareholding which must be in the form of a share certificate
(attestation), either by post to the following address: 6 avenue de
Provence 75452 Paris Cedex 09, or via email to the following
address: serviceproxy@cic.fr, or
investor.relations@novacyt.com, no later than 24
June 2024 inclusive.
• Voting on-line using the
Votaccess portal http://www.actionnaire.cic-marketsolutions.eu
if securities held on Euronext Growth are registered with any
of the following banks: CIC, Natixis, Société Générale, Caceis,
Crédit Agricole, BP2S, BNP Retail, Bourse Direct, ODDO, Rothschild
Martin Maurel, Procapital, Citibank, Deutsche Bank, Bank of New
York or JP Morgan. The Votaccess portal will be open from 3 June
2024 to 25 June 2023 2pm BST/3pm CEST.
• Voting on-line via a broker,
nominee, bank or authorised intermediary. Many intermediaries in
the UK such as Hargreaves Lansdown are now using the Broadridge
ProxyVote on-line voting portal.
Shareholders can register for the AGM and
access the online meeting by visiting
https://reg.lumiengage.com/novacyt-sa-agm-2024/novacytagm2024/Site/Register.
Registrations must be accompanied by formal evidence of
shareholding.
Following registration approval, shareholders
will be able to virtually attend the AGM and vote online during the
meeting if they wish, providing formal evidence of holding has been
provided prior to the meeting.
Shareholders who have already voted (through a
proxy, via their broker, nominee, bank, authorised intermediary,
Votaccess portal or Broadridge ProxyVote) will be allowed to attend
the AGM but will not be able to vote twice.
Following the meeting, a recording of the AGM
will be available on the Company's website at www.novacyt.com/investors.
Contacts
|
Novacyt SA
|
https://novacyt.com/investors
|
|
Lyn Rees, Chief Executive
Officer
|
Via Walbrook
PR
|
|
Steve Gibson, Chief Financial
Officer
|
|
|
SP
Angel Corporate Finance LLP (Nominated Adviser and
Broker)
|
+44 (0)20
3470 0470
|
|
Matthew Johnson / Charlie Bouverat
(Corporate Finance)
Vadim Alexandre / Rob Rees
(Corporate Broking)
|
|
|
|
|
|
Deutsche Numis (Joint
Broker)
|
+44 (0)20
7260 1000
|
|
Freddie Barnfield / Duncan Monteith
/ Michael Palser
|
|
|
|
|
|
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick
Petit
|
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com
/
y.petit@allegrafinance.com
|
|
|
|
|
Walbrook PR
(Financial PR & IR)
Stephanie Cuthbert / Paul McManus
/
Phillip Marriage / Alice
Woodings
|
+44 (0)20
7933 8780 or novacyt@walbrookpr.com
+44
(0)7796 794 663 / +44 (0)7980 541 893
+44
(0)7867 984 082 / +44 (0)7407 804 654
|
|
|
|
|
| |
About Novacyt Group (www.novacyt.com)
Novacyt is an international
molecular diagnostics company providing a broad portfolio of
integrated technologies and services, primarily focused on the
delivery of genomic medicine. The
Company develops, manufactures, and
commercialises a range of molecular assays
and instrumentation to deliver workflows and services that enable
seamless end-to-end solutions from sample to result across multiple
sectors including human health, animal health and environmental.
The Company is divided into three
business segments:
|
Clinical
|
Broad portfolio of human clinical
in vitro diagnostic
products, workflows and services focused on three therapeutic
areas:
·
Reproductive Health: NIPT, Cystic Fibrosis and
other rapid aneuploidy tests
·
Precision Medicine: DPYD genotyping
assay
·
Infectious Diseases: Winterplex, multiplex winter
respiratory PCR panel
|
|
Instrumentation
|
Portfolio of next generation size
selection DNA sample preparation platforms and rapid
PCR machines, including:
· Ranger® Technology: automated DNA sample preparation and
target enrichment technology
· MyGo:
real-time quantitative PCR (qPCR) instruments
|
|
Research Use Only
|
Range of services for the life
sciences industry:
·
Design, manufacture, and supply of
high-performance qPCR assays and workflows for use in human health,
agriculture, veterinary and environmental, to support global health
organisations and the research industry
· Pharmaceutical
research services: whole genome sequencing (WGS) / whole exome
sequencing (WES)
|
Novacyt is headquartered in
Vélizy-Villacoublay in France with offices in the UK (in Stokesley,
Eastleigh and Manchester), Taipei, Singapore, the US and Canada and
has a commercial presence in over 65 countries. The Company is
listed on the London Stock Exchange's AIM market ("NCYT") and on
the Paris Stock Exchange Euronext Growth ("ALNOV").
For more information, please refer
to the website: www.novacyt.com